16:09 EST Cartesian Therapeutics (RNAC) files $400M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Cartesian Therapeutics Reports Promising Phase 2b Trial Results
- Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia
- Needham biotech analyst holds an analyst/industry conference call
- Cartesian to present updated data from Phase 2b trial of Descartes-08